Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Shares Issued (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Issued for 5 consecutive years, with $901000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Shares Issued fell 45.62% to $901000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $4.1 million, a 27.83% increase, with the full-year FY2021 number at $204.2 million, changed N/A from a year prior.
  • Shares Issued was $901000.0 for Q1 2025 at Janux Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $1.7 million in Q1 2024 to a low of -$843000.0 in Q3 2021.
  • A 4-year average of $823750.0 and a median of $1.2 million in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: tumbled 21175.0% in 2021, then grew 4.87% in 2024.
  • Janux Therapeutics' Shares Issued stood at -$843000.0 in 2021, then skyrocketed by 287.43% to $1.6 million in 2023, then rose by 4.87% to $1.7 million in 2024, then tumbled by 45.62% to $901000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Shares Issued are $901000.0 (Q1 2025), $1.7 million (Q1 2024), and $1.6 million (Q1 2023).